Graeme Henderson

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/502401/publications.pdf

Version: 2024-02-01

57 papers 4,148 citations

30 h-index 54 g-index

60 all docs 60 docs citations

60 times ranked

4051 citing authors

#	Article	IF	CITATIONS
1	The anomalous pharmacology of fentanyl. British Journal of Pharmacology, 2023, 180, 797-812.	5.4	38
2	Trends in hospital presentations following analytically confirmed synthetic cannabinoid receptor agonist exposure before and after implementation of the 2016 UK Psychoactive Substances Act. Addiction, 2022, 117, 2899-2906.	3.3	5
3	Changes in the development of opioid tolerance on re-exposure among people who use heroin: A qualitative study. PLoS ONE, 2022, 17, e0269379.	2.5	1
4	The ability of fentanyls and other opioids to increase EMG amplitude in respiratory muscles correlates with their agonist efficacy. FASEB Journal, 2021, 35, .	0.5	1
5	Commentary on Andersen et al .: Time for drug checking for heroin users?. Addiction, 2021, 116, 3113-3114.	3.3	O
6	A Novel G Protein–Biased Agonist at the <i>δ</i> Opioid Receptor with Analgesic Efficacy in Models of Chronic Pain. Journal of Pharmacology and Experimental Therapeutics, 2020, 372, 224-236.	2.5	38
7	Fentanyl depression of respiration: Comparison with heroin and morphine. British Journal of Pharmacology, 2020, 177, 254-265.	5.4	102
8	Critical Assessment of G Protein-Biased Agonism at the \hat{l} 4-Opioid Receptor. Trends in Pharmacological Sciences, 2020, 41, 947-959.	8.7	91
9	A novel G proteinâ€biased agonist at the μ opioid receptor induces substantial receptor desensitisation through G proteinâ€coupled receptor kinase. British Journal of Pharmacology, 2020, , .	5.4	7
10	Morphineâ€induced respiratory depression is independent of βâ€arrestin2 signalling. British Journal of Pharmacology, 2020, 177, 2923-2931.	5.4	182
11	Synthetic cannabinoids and potential cardiac arrhythmia risk: an important message for drug users. Therapeutic Advances in Drug Safety, 2020, 11, 204209862091341.	2.4	11
12	Global patterns of opioid use and dependence: harms to populations, interventions, and future action. Lancet, The, 2019, 394, 1560-1579.	13.7	404
13	Prolonged ethanol administration prevents the development of tolerance to morphine-induced respiratory depression. Drug and Alcohol Dependence, 2019, 205, 107674.	3.2	2
14	How the complex pharmacology of the fentanyls contributes to their lethality. Addiction, 2019, 114, 1524-1525.	3.3	32
15	Ethanol Reversal of Oxycodone Tolerance in Dorsal Root Ganglia Neurons. Molecular Pharmacology, 2018, 93, 417-426.	2.3	5
16	Oxycodoneâ€induced tolerance to respiratory depression: reversal by ethanol, pregabalin and protein kinase C inhibition. British Journal of Pharmacology, 2018, 175, 2492-2503.	5.4	44
17	A new approach to formulating and appraising drug policy: A multi-criterion decision analysis applied to alcohol and cannabis regulation. International Journal of Drug Policy, 2018, 56, 144-152.	3.3	44
18	The novel $\hat{l}^{1}/\hat{a}\in \mathfrak{o}$ pioid receptor agonist PZM21 depresses respiration and induces tolerance to antinociception. British Journal of Pharmacology, 2018, 175, 2653-2661.	5.4	142

#	Article	IF	CITATIONS
19	Emerging areas of opioid pharmacology. British Journal of Pharmacology, 2018, 175, 2715-2716.	5.4	1
20	Risk to heroin users of polydrug use of pregabalin or gabapentin. Addiction, 2017, 112, 1580-1589.	3.3	126
21	Drug Binding Poses Relate Structure with Efficacy in the \hat{l}^4 Opioid Receptor. Journal of Molecular Biology, 2017, 429, 1840-1851.	4.2	26
22	Effect of Tamoxifen and Brain-Penetrant Protein Kinase C and c-Jun N-Terminal Kinase Inhibitors on Tolerance to Opioid-Induced Respiratory Depression in Mice. Journal of Pharmacology and Experimental Therapeutics, 2017, 361, 51-59.	2.5	16
23	Reversal of oxycodone and hydrocodone tolerance by diazepam. Brain Research, 2017, 1674, 84-90.	2.2	5
24	Ethanol Reversal of Tolerance to the Antinociceptive Effects of Oxycodone and Hydrocodone. Journal of Pharmacology and Experimental Therapeutics, 2017, 362, 45-52.	2.5	16
25	Comparison of cannabinoids in hair with selfâ€reported cannabis consumption in heavy, light and nonâ€cannabis users. Drug and Alcohol Review, 2017, 36, 220-226.	2.1	49
26	Ethanol Reversal of Tolerance to the Respiratory Depressant Effects of Morphine. Neuropsychopharmacology, 2016, 41, 762-773.	5.4	61
27	Reply to Wang and Sadée. Psychopharmacology, 2015, 232, 1495-1496.	3.1	0
28	The opioid receptor pharmacology of GSK1521498 compared to other ligands with differential effects on compulsive reward-related behaviours. Psychopharmacology, 2015, 232, 305-314.	3.1	20
29	Ranking the harm of non-medically used prescription opioids in theÂUK. Regulatory Toxicology and Pharmacology, 2015, 73, 999-1004.	2.7	17
30	Role of G Protein–Coupled Receptor Kinases 2 and 3 in <i>μ</i> -Opioid Receptor Desensitization and Internalization. Molecular Pharmacology, 2015, 88, 347-356.	2.3	81
31	The μâ€opioid receptor: an electrophysiologist's perspective from the sharp end. British Journal of Pharmacology, 2015, 172, 260-267.	5.4	9
32	Regulation of <i> Âμ </i> > -Opioid Receptors: Desensitization, Phosphorylation, Internalization, and Tolerance. Pharmacological Reviews, 2013, 65, 223-254.	16.0	673
33	Identification of phosphorylation sites in the <scp>COOH</scp> â€ŧerminal tail of the Î⅓â€opioid receptor. Journal of Neurochemistry, 2013, 124, 189-199.	3.9	41
34	Ethanol Reversal of Cellular Tolerance to Morphine in Rat Locus Coeruleus Neurons. Molecular Pharmacology, 2013, 84, 252-260.	2.3	14
35	μâ€Opioid receptor desensitization: homologous or heterologous?. European Journal of Neuroscience, 2012, 36, 3636-3642.	2.6	22
36	Endomorphin-2: A Biased Agonist at the \hat{l} 4-Opioid Receptor. Molecular Pharmacology, 2012, 82, 178-188.	2.3	88

#	Article	IF	CITATIONS
37	μ-Opioid Receptors: Correlation of Agonist Efficacy for Signalling with Ability to Activate Internalization. Molecular Pharmacology, 2010, 78, 756-766.	2.3	236
38	Câ€terminal splice variants of the μâ€opioid receptor: existence, distribution and functional characteristics. Journal of Neurochemistry, 2008, 104, 937-945.	3.9	20
39	Does alcohol increase the risk of overdose death: the need for a translational approach. Addiction, 2008, 103, 1060-1062.	3.3	67
40	Pre-treatment with a PKC or PKA inhibitor prevents the development of morphine tolerance but not physical dependence in mice. Brain Research, 2008, 1217, 70-77.	2.2	38
41	Methadone: does it really have low efficacy at \hat{l} 4-opioid receptors?. NeuroReport, 2008, 19, 589-593.	1.2	17
42	How important is protein kinase C in $\hat{l}\frac{1}{4}$ -opioid receptor desensitization and morphine tolerance?. Trends in Pharmacological Sciences, 2006, 27, 558-565.	8.7	93
43	75 years of opioid research: the exciting but vain quest for the Holy Grail. British Journal of Pharmacology, 2006, 147, S153-S162.	5.4	294
44	Opioid elevation of intracellular free calcium: Possible mechanisms and physiological relevance. Cellular Signalling, 2006, 18, 151-161.	3.6	35
45	Agonist-Selective Mechanisms of $\hat{l}\frac{1}{4}$ -Opioid Receptor Desensitization in Human Embryonic Kidney 293 Cells. Molecular Pharmacology, 2006, 70, 676-685.	2.3	140
46	Protein Kinase C Activation Enhances Morphine-Induced Rapid Desensitization of $\hat{l}\frac{1}{4}$ -Opioid Receptors in Mature Rat Locus Ceruleus Neurons. Molecular Pharmacology, 2004, 66, 1592-1598.	2.3	83
47	\hat{l} 4-Opioid Receptor Desensitization in Mature Rat Neurons: Lack of Interaction between DAMGO and Morphine. Journal of Neuroscience, 2003, 23, 10515-10520.	3.6	80
48	Properties of native P2X receptors in rat trigeminal mesencephalic nucleus neurones: lack of correlation with known, heterologously expressed P2X receptors. Neuropharmacology, 2001, 40, 96-105.	4.1	27
49	Modulation of fast synaptic transmission by presynaptic ligand-gated cation channels. Journal of the Autonomic Nervous System, 2000, 81, 110-121.	1.9	67
50	Hyperpolarization-activated cationic currents (Ih) in neurones of the trigeminal mesencephalic nucleus of the rat. Journal of Physiology, 1998, 510, 695-704.	2.9	52
51	ATP Receptor-Mediated Enhancement of Fast Excitatory Neurotransmitter Release in the Brain. Molecular Pharmacology, 1998, 54, 372-378.	2.3	139
52	Neuropeptide Y Y2 receptor and somatostatin sst2 receptor coupling to mobilization of intracellular calcium in SH-SY5Y human neuroblastoma cells. British Journal of Pharmacology, 1997, 120, 455-463.	5.4	29
53	Î'―and ι⁄4―pioid receptor mobilization of intracellular calcium in SH‣Y5Y human neuroblastoma cells. British Journal of Pharmacology, 1996, 117, 333-340.	5.4	58
54	The effect of nociceptin on Ca ²⁺ channel current and intracellular Ca ²⁺ in the SH‣Y5Y human neuroblastoma cell line. British Journal of Pharmacology, 1996, 118, 205-207.	5.4	193

#	Article	IF	CITATIONS
55	ELECTROPHYSIOLOGY ANALYSIS OF OPIOD ACHON IN THE CENTRAL NERVOUS SYSTEM. British Medical Bulletin, 1983, 39, 59-64.	6.9	38
56	Role of Acetaldehyde in Ethanol Reversal of Tolerance to Morphine-Induced Respiratory Depression in Mice. Advances in Drug and Alcohol Research, 0, 1 , .	2.5	0
57	Interaction With the Lipid Membrane Influences Fentanyl Pharmacology. Advances in Drug and Alcohol Research, 0, 2, .	2.5	8